

Shao-An Xue, Senior Lecturer in Tumor Immunology and Cancer Immunotherapy, **University College London Medical School**.

Dr Shao-An Xue has been in the field of viral oncology and cancer immunotherapy for 20 years, and has successfully developed a new strategy for cancer immunotherapy based on T cell receptor (TCR) gene transfer. He has been able to demonstrate that T cells transduced with a TCR specific for the Wilm's tumor antigen (WT1-TCR) can recognize their specific targets and selectively kill leukemia progenitor cells, without damage to normal CD34⁺ cells. In vivo studies have shown that these TCR-engineered T cells can eliminate leukemia progenitor cells in situations where control T cells prove ineffective. He received the New Investigator Award from the International Society for Experimental Hematology (ISEH) in 2005 (<http://www.iseh.org/?page=PastNIRecipients>) acknowledging this work. Apart from developing the leukemia specific WT1-TCR, Dr Xue has also developed many other tumor specific TCRs, such as EBV-TCR, CMV-TCR and HBV-TCR, and all of these TCRs are in the first in man clinical trials now. He has thus been listed in the top 15 expert in T cell receptor genes by the 《 **BiomedExperts** 》 (http://www.biomedexperts.com/Concept.bme/29204/T-Cell_Receptor_Genes). Dr Xue received his BSc and MSc degrees in Biochemistry from Shanxi Normal University and North Western University, Xian Shaanxi, P. R. China, in 1982 and 1987, respectively, and his PhD degree in Viral Oncology from Imperial College London, United Kingdom, in 1999.